Clinical Trial

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Investigators plan to conduct a single-arm clinical study of adebelimab, a novel PD-L1 inhibitor, in the neoadjuvant treatment of early or locally advanced high-risk ER+/HER2- breast cancer, to explore whether the addition of immune checkpoint inhibitors to traditional neoadjuvant chemotherapy can improve the pathologic complete response rate (pCR) of patients, evaluate its therapeutic safety, and further analyze the biomarkers of the efficacy of neoadjuvant immunotherapy for ER+/HER2- breast cancer, so as to support the clinical application of the drug.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-11.
Status change: Not Yet Recruiting → Recruiting 2025-06-23
Trial Details
NCT Number NCT06500208
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Breast Cancer
Enrollment 48 participants
Start Date 2024-11-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-26